Aldeyra Therapeutics (NASDAQ:ALDX) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Aldeyra Therapeutics (NASDAQ:ALDXGet Rating) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.02, MarketWatch Earnings reports. During the same period in the previous year, the firm earned ($0.25) EPS.

NASDAQ ALDX traded down $0.07 on Friday, hitting $2.71. The company had a trading volume of 1,000,556 shares, compared to its average volume of 689,788. The company’s fifty day moving average price is $4.15 and its 200-day moving average price is $5.21. The company has a debt-to-equity ratio of 0.08, a current ratio of 19.77 and a quick ratio of 19.77. Aldeyra Therapeutics has a 12-month low of $2.65 and a 12-month high of $13.18.

ALDX has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Aldeyra Therapeutics in a research report on Wednesday, April 27th. StockNews.com initiated coverage on Aldeyra Therapeutics in a research report on Thursday, March 31st. They set a “sell” rating for the company. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $17.00.

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA increased its holdings in Aldeyra Therapeutics by 370.1% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 8,664 shares of the biotechnology company’s stock worth $76,000 after acquiring an additional 6,821 shares in the last quarter. Morgan Stanley increased its holdings in Aldeyra Therapeutics by 29.0% in the 1st quarter. Morgan Stanley now owns 16,375 shares of the biotechnology company’s stock worth $194,000 after acquiring an additional 3,680 shares in the last quarter. Invesco Ltd. purchased a new stake in Aldeyra Therapeutics in the 2nd quarter worth $199,000. MetLife Investment Management LLC increased its holdings in Aldeyra Therapeutics by 98.7% in the 4th quarter. MetLife Investment Management LLC now owns 18,715 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 9,298 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Aldeyra Therapeutics in the 4th quarter worth $130,000. 62.94% of the stock is owned by institutional investors.

About Aldeyra Therapeutics (Get Rating)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

Read More

Earnings History for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.